about
Nonpharmacological Interventions for ADHD: Systematic Review and Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological TreatmentsEfficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study dataServices for adults with ADHD: work in progress: Commentary on . . . Specialist adult ADHD clinics in East AngliaPractitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescentsPredictive classification of individual magnetic resonance imaging scans from children and adolescents.An inventory of European data sources for the long-term safety evaluation of methylphenidateStimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients.Study protocol for a randomized controlled trial comparing the efficacy of a specialist and a generic parenting programme for the treatment of preschool ADHD.A systematic review of the safety of lisdexamfetamine dimesylate.Avoiding the 'twilight zone': recommendations for the transition of services from adolescence to adulthood for young people with ADHD.European guidelines on managing adverse effects of medication for ADHD.Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trialTreatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challengesHealth-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.Occupational issues of adults with ADHD.Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations].Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.The quality of life of children with attention deficit/hyperactivity disorder: a systematic review.Towards an ICF core set for ADHD: a worldwide expert survey on ability and disability.Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway.Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidateHealth-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls.The validity, reliability and normative scores of the parent, teacher and self report versions of the Strengths and Difficulties Questionnaire in ChinaProspective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey.Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale.Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorderEfficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.The impact of ADHD on the health and well-being of ADHD children and their siblings.The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010).Practitioner review: Quality of life in child mental health--conceptual challenges and practical choices.Molecular genetics of attention-deficit/hyperactivity disorder: an overviewThe impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review.Do the diagnostic criteria for ADHD need to change? Comments on the preliminary proposals of the DSM-5 ADHD and Disruptive Behavior Disorders Committee.Pragmatic measures in paediatric psychopharmacology--are we getting it right?
P50
Q22241854-A498E8F8-64FD-4E1B-86A9-F2BD829A8AECQ24805432-4C53BA2A-77F0-4226-821D-595E8F71D10BQ26801881-2A4A81AC-6F50-4BED-BE24-2582E3EE3D20Q28282770-FE7254BF-5367-4044-BB9E-77031AF2CD95Q30559710-0064DDD4-0DEA-42CB-8864-5B1A4E15B3ADQ30603225-2C77119E-7927-4D79-A2C1-019C6F478EBCQ33590979-4F035CCB-1F1F-4D5E-8A04-5F5725DCBF38Q33608183-26CDD0F0-A18D-4EE9-825C-91C66DF743F0Q33755396-FA82A585-0162-4841-907C-08FBADDFDB1EQ34066407-FE7AE890-A226-401A-A48C-22ACF648EC4AQ34448884-DEE27600-780F-47FB-99B9-E9C8CEF9CC6BQ34449469-04E5376A-625D-48BB-8AC5-2CB4FCC2E474Q34459431-3826E820-9EB8-498F-AC1D-15F38EE037EDQ34580449-192F2746-E5A8-4020-9487-002A16BD296CQ34580471-1914F4B9-9E09-44B3-8792-D08446BC2446Q34588668-214D4155-3C14-44D0-9236-F8688AB56659Q34676317-083ED087-FD31-4D9D-AEC4-EB11356D2566Q34795495-4D6EB3C5-844F-4C7B-A10D-C546DE4D5D09Q35001357-639DF99F-D52D-4D76-A16D-507822E02C6EQ35084047-9126E788-9520-4E03-9DD5-152EBA77F09AQ36289924-7BB8ABB6-8CA0-466D-AFB6-DA7D69493A20Q36298408-A46FE60E-D7A7-4670-BDD8-3D7AAAFE1ED2Q36471058-8AA0FB4A-B936-43BC-B28E-FBD3FC2F28D9Q36526984-F958FF7B-F9EF-43DD-B9A8-048A86C8308BQ36626188-329E135F-FDA5-44B2-8AE9-699BF4BC74A3Q36693563-4AA88C5B-1BDF-42C2-9C4C-438CC5FD0E35Q36861122-0D5EF3EE-0486-4E5D-B942-37FE6585C76EQ36986830-D24A3595-AF91-400F-9F48-543346E1070BQ37085902-37333DDC-C3DB-4F6F-BC14-9FE8FAAC590AQ37115696-F67F160C-BAC1-4801-982B-3DE16B7D30FBQ37190637-6EE99ECB-DE57-4A14-8E62-156E1E37B874Q37199815-E4BA7825-DF68-4663-A72E-01423346CF21Q37330660-1D84F753-6477-4857-8767-1426E8B35B70Q37373172-39406FC2-E051-41D3-A173-345E56530192Q37376766-6374A0D2-985D-4968-AAC4-FD535457A27BQ37477275-1D3BA636-66E6-40C8-A95E-198EB78B85D9Q37690166-65691E89-894C-487A-9958-2304B70BEF4BQ37788677-FBC1EACB-29E0-4804-BCE9-D5D02C278B16Q37812317-11534C86-7D73-4DDB-97CA-9D4C9C9E7367Q37824946-DAD4C2BB-F071-4728-A909-327CA2E17DFF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
David Coghill
@ast
David Coghill
@en
David Coghill
@es
David Coghill
@nl
David Coghill
@sl
type
label
David Coghill
@ast
David Coghill
@en
David Coghill
@es
David Coghill
@nl
David Coghill
@sl
altLabel
Coghill D
@en
prefLabel
David Coghill
@ast
David Coghill
@en
David Coghill
@es
David Coghill
@nl
David Coghill
@sl
P1006
P214
P244
P1006
P1053
B-7244-2009
P106
P21
P213
0000 0000 4065 0551
P214
P244
n2008184433
P31
P3829
P496
0000-0003-3017-9737
P734
P735
P7859
lccn-n2008184433